Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.
Blauvelt A, Thyssen JP, Guttman-Yassky E, Bieber T, Serra-Baldrich E, Simpson E, Rosmarin D, Elmaraghy H, Meskimen E, Natalie CR, Liu Z, Xu C, Pierce E, Morgan-Cox M, Garcia Gil E, Silverberg JI.
Blauvelt A, et al. Among authors: pierce e.
Br J Dermatol. 2023 May 24;188(6):740-748. doi: 10.1093/bjd/ljad022.
Br J Dermatol. 2023.
PMID: 36994947
Clinical Trial.